JP7227913B2 - 血液悪性腫瘍患者の治療方法 - Google Patents

血液悪性腫瘍患者の治療方法 Download PDF

Info

Publication number
JP7227913B2
JP7227913B2 JP2019545304A JP2019545304A JP7227913B2 JP 7227913 B2 JP7227913 B2 JP 7227913B2 JP 2019545304 A JP2019545304 A JP 2019545304A JP 2019545304 A JP2019545304 A JP 2019545304A JP 7227913 B2 JP7227913 B2 JP 7227913B2
Authority
JP
Japan
Prior art keywords
flt3
leukemia
cell
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019545304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508313A5 (enExample
JP2020508313A (ja
Inventor
ウィリアム ジー． ライス，
ジュン ミョン チョ，
ヨンレ ホン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CrystalGenomics Inc
Original Assignee
CrystalGenomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CrystalGenomics Inc filed Critical CrystalGenomics Inc
Publication of JP2020508313A publication Critical patent/JP2020508313A/ja
Publication of JP2020508313A5 publication Critical patent/JP2020508313A5/ja
Priority to JP2022197816A priority Critical patent/JP7431309B2/ja
Application granted granted Critical
Publication of JP7227913B2 publication Critical patent/JP7227913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019545304A 2017-02-21 2018-02-21 血液悪性腫瘍患者の治療方法 Active JP7227913B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022197816A JP7431309B2 (ja) 2017-02-21 2022-12-12 血液悪性腫瘍患者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762461584P 2017-02-21 2017-02-21
US62/461,584 2017-02-21
US201762578948P 2017-10-30 2017-10-30
US62/578,948 2017-10-30
PCT/US2018/018951 WO2018156578A1 (en) 2017-02-21 2018-02-21 Methods for treating patients with hematologic malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022197816A Division JP7431309B2 (ja) 2017-02-21 2022-12-12 血液悪性腫瘍患者の治療方法

Publications (3)

Publication Number Publication Date
JP2020508313A JP2020508313A (ja) 2020-03-19
JP2020508313A5 JP2020508313A5 (enExample) 2021-04-08
JP7227913B2 true JP7227913B2 (ja) 2023-02-22

Family

ID=63253344

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019545304A Active JP7227913B2 (ja) 2017-02-21 2018-02-21 血液悪性腫瘍患者の治療方法
JP2022197816A Active JP7431309B2 (ja) 2017-02-21 2022-12-12 血液悪性腫瘍患者の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022197816A Active JP7431309B2 (ja) 2017-02-21 2022-12-12 血液悪性腫瘍患者の治療方法

Country Status (11)

Country Link
US (2) US20180344702A1 (enExample)
EP (1) EP3585778A4 (enExample)
JP (2) JP7227913B2 (enExample)
KR (1) KR20190128646A (enExample)
CN (1) CN110621665A (enExample)
AU (2) AU2018225539B2 (enExample)
CA (1) CA3054196A1 (enExample)
IL (1) IL268736A (enExample)
MX (1) MX2019009954A (enExample)
TW (1) TWI821174B (enExample)
WO (1) WO2018156578A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US20200171001A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
US20240091226A1 (en) * 2021-01-05 2024-03-21 Sumitomo Pharma Oncology, Inc. Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN120857931A (zh) * 2022-12-10 2025-10-28 艾普托斯生物科学公司 用于治疗患有血液学恶性病的患者的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
JP2016504351A (ja) 2012-12-28 2016-02-12 クリスタルジェノミクス・インコーポレイテッドＣｒｙｓｔａｌｇｅｎｏｍｉｃｓ， Ｉｎｃ． Ｂｔｋキナーゼ抑制剤としての２，３−ジヒドロ−イソインドール−１−オン誘導体及びこれを含む薬学的組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463658B2 (en) * 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
EP3062809B1 (en) * 2013-10-31 2020-07-08 Biokine Therapeutics Ltd. A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
JP2016504351A (ja) 2012-12-28 2016-02-12 クリスタルジェノミクス・インコーポレイテッドＣｒｙｓｔａｌｇｅｎｏｍｉｃｓ， Ｉｎｃ． Ｂｔｋキナーゼ抑制剤としての２，３−ジヒドロ−イソインドール−１−オン誘導体及びこれを含む薬学的組成物

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ACS chemical biology，2016年，DOI: 10.1021/acschembio.6b00480
Blood，2012年，Vol. 120, No. 21, 156，pp. 1-3
Blood，2012年，Vol. 120, No. 21, 2569，pp. 1-3
Blood，2012年，Vol. 120, No. 21, 686，pp. 1-4
BLOOD，2015年，Vol. 125, No. 12，pp. 1936-1947
Blood，2015年，Vol. 126, No. 23, 5117，pp. 1-3
Oncogene，2015年，Vol. 34，pp. 2426-2436
SCIENTIFIC REPORTS，2015年，Vol. 5: 12949，pp. 1-9
ファルマシア，2016年，Vol. 52, No. 5，p. 441

Also Published As

Publication number Publication date
CN110621665A (zh) 2019-12-27
MX2019009954A (es) 2019-12-19
AU2018225539B2 (en) 2022-07-14
EP3585778A4 (en) 2020-12-02
TWI821174B (zh) 2023-11-11
IL268736A (en) 2019-10-31
AU2022252696B2 (en) 2025-01-30
TW201842906A (zh) 2018-12-16
JP2023022330A (ja) 2023-02-14
US20180344702A1 (en) 2018-12-06
CA3054196A1 (en) 2018-08-30
WO2018156578A1 (en) 2018-08-30
AU2022252696A1 (en) 2022-11-03
KR20190128646A (ko) 2019-11-18
US20230012148A1 (en) 2023-01-12
JP2020508313A (ja) 2020-03-19
AU2018225539A1 (en) 2019-09-05
JP7431309B2 (ja) 2024-02-14
EP3585778A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
JP7431309B2 (ja) 血液悪性腫瘍患者の治療方法
JP7427098B2 (ja) タンパク質キナ－ゼ阻害活性を有する７－アミノ－３，４－ジヒドロピリミドピリミジン－２－オン誘導体およびこれを含む治療用薬学組成物
EP4395775A1 (en) Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
JP6114820B2 (ja) プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用
CN118221698A (zh) Kras g12d抑制剂
RS65884B1 (sr) Makrociklična jedinjenja i primene istih
CN109153669B (zh) 苯甲酰胺类化合物的新晶型
JP6979595B2 (ja) プロテインキナーゼ阻害剤としてのアミノチアゾール化合物
RU2550346C2 (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
JP2022521380A (ja) Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
TW201902892A (zh) 化合物
JP2019526617A (ja) 治療用化合物
JP2022509257A (ja) ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法
HK40014760A (en) Methods for treating patients with hematologic malignancies
EP4441052B1 (en) Compounds
KR101995533B1 (ko) [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
Ma ALKYNYL AMINOISOQUINOLINES, NOVEL FLT3 KINASE INHIBITORS WITH POTENT ACTIVITY AGAINST ACUTE MYELOID LEUKEMIA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221212

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221220

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230210

R150 Certificate of patent or registration of utility model

Ref document number: 7227913

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250